Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience

J G Schrama, M J Holtkamp, J W Baars, J H Schornagel, S Rodenhuis, J G Schrama, M J Holtkamp, J W Baars, J H Schornagel, S Rodenhuis

Abstract

High-dose chemotherapy (HD-CT) has a role in the potentially curative treatment of several tumours. The relative efficacies of the different regimens have not been studied in comparative trials, but it is clear that toxicities differ significantly between them. We analysed the immediate and long-term toxicity in the first 100 consecutive patients treated with the CTC regimen (cyclophosphamide 6000 mg m(-2), carboplatin 1600 mg m(-2) (or 20 mg ml(-1) min under the curve (AUC)) both as daily 1 h infusion, thiotepa 480 mg m(-2) as twice daily 30 min infusion, all divided over 4 consecutive days) followed by peripheral blood progenitor cell reinfusion (PBPC-Tx). Most patients had high-risk (n=86) or metastatic (n=4) breast cancer, or a germ cell tumour (n=8). Two patients (with a medulloblastoma and an aesthesioneuroblastoma, respectively) received CTC as off-protocol salvage regimen. The main toxicity was bone marrow suppression. Most patients had PBPC-Tx with granulocyte colony-stimulating factor (G-CSF), and the median time to neutrophil count 500 x 10(6) l(-1) and platelet count >20 x 10(9) l(-1) without transfusion independence was 10 (range 8-25) and 13 (8-60) days, respectively. The toxic death rate was 1%. Other frequent toxicities were neutropenic fever requiring antibiotics (n=65), central catheter-related infection (n=12) or a bleeding episode (n=48), mostly epistaxis (n=26). Reversible cardiac toxicity was seen in six patients and pulmonary events occurred in seven patients (infection (n=6), embolism (n=1)). Grade 3-4 gastrointestinal toxicity was frequent: nausea and vomiting 55%, diarrhoea 28% and mild liver toxicity (transaminase elevations) 9%. One patient pretreated with cisplatin had a kidney transplantation 8 years after HD-CT. Late complications included reversible radiation pneumonitis (n=12) and chronic heart failure (n=2). We found five second solid malignancies and two myelodysplasias. In conclusion, the CTC regimen is associated with a moderate, mainly reversible, toxicity. Future studies need to compare the efficacy and toxicity of the different HD-CT regimens.

References

    1. Anderson LW, Chen TL, Colvin OM, Grochow LB, Collins JM, Kennedy MJ, Strong JM (1996) Cyclophosphamide and 4-hydroxyphosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Clin Cancer Res 2: 1481–1487
    1. Antman KH, Ayash, Elias A, Wheeler C, Hunt M, Eder JP, Teider BA, Critchlow J, Bibbo J, Schnipper LE, Frei III E (1992) A phase II study of high-dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10: 102–110
    1. Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JN, Fields KK, Freytas CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, Mc Carthy Jr PL, Saez L, Spitzer G, Stadtmauer GA, Williams ST, Wolff S, Sobienski KA, Armitrage JO, Horowitz MM (1997) High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15: 1870–1879
    1. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminin E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356: 1384–1391
    1. De Gast GC, Vyth-Dreese FA, Nooijen W, van den Bogaard CJ, Sein J, Holtkamp MM, Linthorst GA, Baars JW, Schornagel JH, Rodenhuis S (2002) Reinfusion of autologous lymphocytes with granulocyte–macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancer. J Clin Oncol 20: 58–64
    1. van Dam FS, Schagen SB, Muller MJ, Boogerd W, van der Wall E, Droogleever- Fortuyn ME, Rodenhuis S (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90: 210–218
    1. Huitema AD, Kerbusch T, Tibben MM, Rodenhuis S, Beijnen JH (2000) Reduction of cyclophosphamide-bioactivation by thiotepa: critical sequence dependency in high-dose regimens. Cancer Chemother Pharmacol 46: 119–127
    1. Huitema AD, Mathot R, Tibben MM, Rodenhuis S, Beijnen J (2001) Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen. Ther Drug Monit 23: 650–657
    1. Huitema ADR, Spaander M, Mathot RAA, Tibben MM, Holtkamp MM, Beijnen JH, Rodenhuis S (2002) Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol 13: 374–384
    1. Hussein AM, Petros WP, Ross M, Vredenburgh JJ, Affrontil ML, Jones RB, Shpall EJ, Rubin P, Elkordy M, Gilbert C, Gupton C, Egorin MJ, Soper J, Berchuck A, Clarke-Person D, Berry DA, Peters WP (1996) A phase I/II study of high-dose cyclophosphamide, cisplatin and thiotepa followed by autologous bone marrow and granulocyte colony stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. Cancer Chemother Pharmacol 37: 561–568
    1. NCI (1998) Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD: Division of Cancer treatment, National Cancer Institute
    1. Nikcevich DA, Vredenburgh JJ, Broadwater G, Ross M, Shpall EJ, Jones RB, Marks L, Peters WP (2002) Ten years follow-up after high-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Proc Am Soc Clin Oncol 18: 415a (abstract 1657)
    1. Peters WP, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson D, Marks L, Cincine C, Wood W, Henderson I, Hurd D, Norton L (1999) A prospective, randomized comparision of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes; preliminary results of CALGB 9083/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 18: 1a (abstract 2)
    1. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurzberg J, Bast Jr RC, Jones R, Shpall E (1993) High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11: 1132–1143
    1. Przepiorka D, Madden T, Ippoliti C, Esrov Z, Dimopoulis M (1995) Dosing of thiotepa for myeloablative therapy. Cancer Chemother Pharmacol 37: 155–160
    1. Roche H, Pouillart P, Meyer N, Biron M, Speilmann M, Janvier M, Spaelh D, Fabbro M, Linassier C, Deny B, Asselain B (2001) Adjuvant high-dose chemotherapy (HDC) improves early outcome for high-risk (N>7) breast cancer patients: the Pegase 01 trial. Proc Am Soc Clin Oncol 20: 26a (abstract 102)
    1. Rosti G, Ferrante P (2001) EBMT Solid Tumors Working Party and Registry 2000 Report. Faenza, Italy: CELI Edizione
    1. Rodenhuis S (2000) The status of high-dose chemotherapy in breast cancer. Oncologist 5: 369–375
    1. Rodenhuis S, Baars JW, Schornagel JH, Vlasveld LT, Mandjes I, Pinedo HM, Richel DJ (1992) Feasibility and toxicity study of a high-dose regimen incorporating carboplatin, cyclophosphamide and thiotepa. Ann Oncol 3: 855–860
    1. Rodenhuis S, Bontenbal M, Beex L, van der Wall E, Richel D, Nooij M, Voest E, Hupperets P, Westermann A, Dalesio O, de Vries E (2000) Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymphnodes. Proc Am Soc Clin Oncol 19: 74a (abstract 286)
    1. Rodenhuis S, Richel D, van der Wall E, Schornagel JH, Baars JW, Koning CC, Peterse JC, Borger JK, Nooijen WJ, Bakx R, Dalesio O, Rutgers E (1998) Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph node involvement. Lancet 352: 515–521
    1. Rodenhuis S, Westermann A, Holtkamp MJ, Nooijen WJ, Baars JW, van de Wall E, Slaper-Cortenbach IC, Schornagel JH (1996) Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 14: 1473–1483
    1. Rodenhuis S, de Wit R, de Mulder PH, Keizer HJ, Sleijfer DT, Lalisang RI, Bakker PJ, Manjes I, Kooi M, de Vries EG (1999) A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 10: 1467–1473
    1. Schagen SB, Hamburger HL, Muller MJ, Boogerd W, van Dam FS (2001) Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurol Oncol 51: 159–165
    1. Schrama JG, Baars JW, Holtkamp MJ, Schornagel JH, Beijnen JH, Rodenhuis S (2001) Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer. Bone Marrow Transplant 28: 173–180
    1. Schrama JG, Faneyte IF, Schornagel JH, Baars JW, Peterse JC, van de Vijver MJ, Dalesio O, van Tinteren H, Rutgers E, Richel DJ (2002) Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol 13: 689–698
    1. Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 342: 1069–1076
    1. Teicher BA, Holden SA, Eder JP, Herman TS, Antman KA, Frei III E (1999) Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Semin Oncol 17: 18–32
    1. Van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–536
    1. van der Wall E, Nooijen WJ, Baars JW, Holtkamp MJ, Schorangel JH, Richel DJ, Rutgers EJ, Slaper-Cortenbach IC, van der Schoot CE, Rodenhuis S (1995) High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer. Br J Cancer 71: 857–862
    1. Westermann AM, Holtkamp MM, Linthorst GA, van Leeuwen L, Willemse EJ, van Dijk WC, Nooijen WJ, Baars JW, Schornagel JH, Rodenhuis S (1999) At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. Ann Oncol 10: 511–517
    1. Wolff SN, Herzig RH, Fay JW, LeMaistre CF, Brown RA, Frei-Lahr D, Stranjord S, Giannone L, Coccia P, Weick JL (1990) High-dose N, N′, N″-triethyl-enethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol 17(Suppl 3): 2–6

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe